Respiri limited logo
Respiri Limited


Over 330 million people worldwide suffer from asthma alone, with the global market for asthma and chronic obstructive pulmonary disease (COPD) estimated to be worth $47 billion this year.

Respiri Ltd (ASX: RSH) looks to be quickly progressing its path to commercialisation with a portfolio of devices and software that meet the needs of this vast addressable market.

Not only is the company on the precipice of signing landmark agreements in China for its asthma monitoring device, it has also been given the go-ahead for European sales of its next generation wheeze detection and monitoring device into the European market, including the UK.

Imagine an over the counter, non-prescription product that can help people with asthma lead better lives.

RSH is currently focussed on securing partnership agreements to help launch a new generation of its continuous monitoring system.

The company expects to announce that within weeks it will receive written commercial-in-confidence proposals from at least two partners in China — a country for which significant improvements in asthma monitoring and management is required.

The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

The anticipated incoming agreements could involve the production of the company’s next generation device, plus sales and distribution.

As such there could be a raft of news to come for this $20 million capped med tech company on the back of its agreements in China and entry in the European market.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!